Nano24med
Tel‑Aviv, Israel· Est.
Exosome‑delivered CD24 immunomodulator for ARDS and cytokine‑storm diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Exosome‑delivered CD24 immunomodulator for ARDS and cytokine‑storm diseases.
ImmunologyRespiratory DiseasesCritical Care
Technology Platform
Exosome‑based delivery of CD24, an innate immune checkpoint protein, administered by inhalation to suppress cytokine‑storm‑driven inflammation.
Opportunities
Expansion of EXO‑CD24 into sepsis and autoimmune indications, and potential partnerships with large pharma for global commercialization.
Risk Factors
Clinical efficacy uncertainty, scaling exosome manufacturing, and navigating regulatory pathways for nanocarrier biologics.
Competitive Landscape
Competes with steroid therapies, monoclonal antibodies, and other exosome‑based platforms; differentiation lies in targeted CD24 modulation and inhaled delivery.